The development of new technologies has stimulated a crusade of screening for earlier detection of prostate cancer. This effort has resulted in controversy regarding its clinical use in this format. Until randomized clinical screening trials define the value of prostate cancer screening, clinicians who use screening approaches must gain a strong understanding of the natural history of the disease, the strengths and weaknesses of available screening methodologies, and epidemiologic considerations of prostate cancer risk.